updated 5/9/2011 7:15:36 AM ET 2011-05-09T11:15:36

DALLAS, May 9, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring DepoMed Inc. (Nasdaq:DEPO). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/DEPO

DepoMed Inc. (DEPO) is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies. Since its inception, the Company has advanced two products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations.

This newsletter has been helping traders make great investment decisions on DEPO; click here for a 25% discount offer.

In the report, the analyst notes:

"DEPO shares advanced Friday after the drug maker reported additional positive Phase III data for Gralise, the Company's once-daily formulation of gabapentin for management of postherpetic neuralgia (PHN)."

"DEPO has secured U.S. FDA approval for Gralise in January this year. Two months later, DEPO and its former licensee, Abbott Products, terminated their Gralise exclusive license agreement and the rights to Gralise reverted back to DEPO. The drug is expected to be available in pharmacies by the end of the year."

To read the entire report visit: www.microstockprofit.com/lp/DEPO

See what investors are saying about DEPO at http://www.stockhideout.com

Get breaking news on DEPO at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 5.09%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.67%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.34%
13.32%
Cash Back Cards 17.82%
17.81%
Rewards Cards 17.07%
17.06%
Source: Bankrate.com